Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Aug 18;10(1):37-44.
doi: 10.1097/XCE.0000000000000230. eCollection 2021 Mar.

Androgen receptor-reduced sensitivity is associated with increased mortality and poorer glycaemia in men with type 2 diabetes mellitus: a prospective cohort study

Adrian H Heald  1   2 , Ghasem Yadegar Far  1   3 , Mark Livingston  4 , Helene Fachim  1   2 , Mark Lunt  1 , Ram Prakash Narayanan  5 , Kirk Siddals  1 , Gabriela Moreno  6 , Richard Jones  1   7 , Nagaraj Malipatil  1   2 , Martin Rutter  1   8 , Martin Gibson  1   2 , Rachelle Donn  1 , Geoff Hackett  9 , Hugh Jones  10   11
Affiliations

Androgen receptor-reduced sensitivity is associated with increased mortality and poorer glycaemia in men with type 2 diabetes mellitus: a prospective cohort study

Adrian H Heald et al. Cardiovasc Endocrinol Metab. .

Abstract

Introduction: Hypogonadism is associated with poorer glycaemic outcomes/increased all-cause and cardiovascular morbidity/mortality in type 2 diabetes mellitus (T2DM). Increasing CAG repeat number within exon-1 of the androgen receptor (AR) gene is associated with increased AR resistance/insulin resistance.

Methods: We determined in a long-term 14-year follow-up cohort of 423 T2DM Caucasian men, the association between baseline androgen status/CAG repeat number (by PCR then Sequenom sequencing) and metabolic/cardiovascular outcomes.

Results: Metabolic outcomes: Lower total testosterone was associated with higher BMI (kg/m2) at 14-year-follow-up: regression coefficient -0.30 (95% confidence interval -0.445 to -0.157), P = 0.0001. The range of CAG repeat number was 9-29 repeats. Higher CAG repeat number in exon-1 of the AR gene was associated with higher follow-up HbA1c2016 - each unit increase in CAG repeat-associated with an increment of 0.1% in HbA1C2016 (P = 0.04), independent of baseline testosterone. Cardiovascular outcomes and mortality: At an average of 14-year-follow-up, 55.8% of hypogonadal men had died vs 36.1% of eugonadal men (P = 0.001). There was a 'u' shaped relation between number of CAG repeats and mortality. Twenty-one CAG repeats were associated with an up to nearly 50% lower mortality rate than <21 CAG repeats and >21 CAG repeats - independent of baseline testosterone level.

Conclusion: A higher number of CAG repeats at the AR gene associates with higher future HbA1c. There was a 'u' shaped relation between CAG repeat number and mortality rate. Determination of CAG repeat number may become part of assessment of androgen status/its consequences for men with T2DM.

Keywords: BMI; androgen receptor; cardiovascular; mortality; testosterone; type 2 diabetes.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

Figures

Fig. 1
Fig. 1
Frequency distribution of CAG repeat number.
Fig. 2
Fig. 2
Relation between CAG repeat number and BMI 2016. Each unit increase in CAG repeat associated with an increment of 0.43 in BMI 2016 (P = 0.018).
Fig. 3
Fig. 3
Relation between CAG repeat number and HbA1c 2016. Each unit increase in CAG repeat associated with an increment of 0.1% in HbA1C 2016 (P = 0.04).
Fig. 4
Fig. 4
Relation between GAC repeat number and mortality rate. Adjusted logistic regression indicated that the presence of 21 CAG repeats reduced the risk of death by 45% compared with <21 CAG repeats [odds ratio 0.55 (95% CI 0.28–0.92), P = 0.02]; and that >21 repeats increased the risk of death by 48% [odds ratio 1.48 (95% CI 1.08–2.37, P = 0.015]. CI, confidence interval.
See this image and copyright information in PMC

References

    1. Kaiser AB, Zhang N, Van Der Pluijm W. Global prevalence of type 2 diabetes over the next ten years (2018-2028). Diabetes. 2018; 67 (Suppl 1):202-LB.
    1. Anupam B, Shivaprasad C, Sridevi A, Aiswarya Y, Gautham K, Ramdas B, Kejal S. Association of total and calculated free testosterone with androgen deficiency symptoms in patients with type 2 diabetes. Int J Impot Res. 2020; 32:289–296. - PubMed
    1. Kapoor D, Jones TH. Androgen deficiency as a predictor of metabolic syndrome in aging men: an opportunity for intervention? Drugs Aging. 2008; 25:357–369. - PubMed
    1. Khripun I, Vorobyev S, Belousov I, Kogan M, Zitzmann M. Influence of testosterone substitution on glycemic control and endothelial markers in men with newly diagnosed functional hypogonadism and type 2 diabetes mellitus: a randomized controlled trial. Aging Male. 2019; 22:241–249. - PubMed
    1. Morgunov LY, Denisova IA, Rozhkova TI, Stakhovskaya LV, Skvortsova VI. Hypogonadism and its treatment following ischaemic stroke in men with type 2 diabetes mellitus. Aging Male. 2020; 23:71–80. - PubMed